INDUSTRY members are up in
arms over the Federal
Government’s decision to reject the
Senate Committee’s
recommendation to reinstate the
‘$10 million rule’.
“This was the government’s
opportunity to shut down the
deferral issue once and for all,” CE
of AstraZeneca Australia, Mark
Fladrich told media.
The $10 million rule basically
meant that drugs which had received
a positive recommendation by an
independent committee for PBS
listing and which would cost less
than $10 million per annum, could
bypass the Cabinet approval process.
The Senate inquiry kicked-off
after the Government’...
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 14 Aug 12
Established in 2007, Pharmacy Daily is Australia's leading pharmacy industry publication, and is sent as a free subscription to people across the industry as a PDF newsletter every weekday.
To sign up for a free subscription, click on the button at right.
